Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta
- 1 November 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 70 (5) , 1014-1024
Abstract
Preeclampsia is a major pregnancy complication associated with poor placental perfusion and placental hypoxia. Systemic and placental inflammation and elevated placental secretion of the antiangiogenic factors sFlt-1 (soluble fms-like tyrosine kinase 1) and sEng (soluble endoglin) are hallmarks of preeclampsia, causing endothelial dysfunction and multiorgan injury. A molecule that links placental hypoxia, inflammation, and antiangiogenic factor release has not been described. ATF3 (activating transcription factor 3) is highly expressed in placenta. We assessed whether placental ATF3 is dysregulated in preterm preeclampsia, is altered by hypoxia, and regulates proinflammatory cytokine and antiangiogenic factor production. ATF3 mRNA and protein expression was significantly reduced in preterm preeclamptic placentas compared with gestation-matched controls. Hypoxia reduced ATF3 expression in primary cytotrophoblast and placental explants. Silencing ATF3 in primary cytotrophoblast increased proinflammatory cytokine (IL-6 [interleukin 6], TNF-α [tumor necrosis factor α]) and NF-κB (nuclear factor κB) expression. In silico analysis identified an ATF3–binding site in the promoter of Flt-1 (the transcript from which sFlt-1 is produced). Silencing ATF3 increased sFlt-1 and sEng secretion from primary cytotrophoblast possibly by increasing Rab11a and Arf1, cargo proteins that facilitate exosomal release of sFlt-1. ATF3 knockout mice did not have a preeclampsia phenotype, suggesting that these pathways may be specific to humans (preeclampsia is a uniquely human condition). To conclude, we have shown that ATF3 is decreased in preeclamptic placentas and that this decrease is likely to occur after prolonged hypoxia. We show that ATF3 is a regulator of placental proinflammatory cytokines and antiangiogenic factors sFlt-1 and sEng. Therefore, reduced ATF3 may be centrally involved in the pathology of preeclampsia.Keywords
This publication has 40 references indexed in Scilit:
- Abnormal Placentation, Angiogenic Factors, and the Pathogenesis of PreeclampsiaObstetrics and Gynecology Clinics of North America, 2010
- Systemic Inflammatory Priming in Normal Pregnancy and Preeclampsia: The Role of Circulating Syncytiotrophoblast MicroparticlesThe Journal of Immunology, 2007
- Soluble endoglin contributes to the pathogenesis of preeclampsiaNature Medicine, 2006
- Latest Advances in Understanding PreeclampsiaScience, 2005
- Pre-eclampsiaThe Lancet, 2005
- Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsiaJournal of Clinical Investigation, 2003
- Preeclampsia: An excessive maternal inflammatory response to pregnancyAmerican Journal of Obstetrics and Gynecology, 1999
- Increased levels of cytokines and cytokine activity modifiers in normal pregnancyEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1994
- Immunoreactive tumor necrosis factor-α is elevated in maternal plasma but undetected in amniotic fluid in the second trimesterAmerican Journal of Obstetrics and Gynecology, 1994
- Tumor necrosis factor-α is elevated in plasma and amniotic fluid of patients with severe preeclampsiaAmerican Journal of Obstetrics and Gynecology, 1994